1. Home
  2. AVDL vs FDUS Comparison

AVDL vs FDUS Comparison

Compare AVDL & FDUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • FDUS
  • Stock Information
  • Founded
  • AVDL 2015
  • FDUS 2011
  • Country
  • AVDL Ireland
  • FDUS United States
  • Employees
  • AVDL N/A
  • FDUS N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • FDUS Finance/Investors Services
  • Sector
  • AVDL Health Care
  • FDUS Finance
  • Exchange
  • AVDL Nasdaq
  • FDUS Nasdaq
  • Market Cap
  • AVDL 764.3M
  • FDUS 759.3M
  • IPO Year
  • AVDL 1996
  • FDUS 2011
  • Fundamental
  • Price
  • AVDL $7.91
  • FDUS $22.09
  • Analyst Decision
  • AVDL Strong Buy
  • FDUS
  • Analyst Count
  • AVDL 7
  • FDUS 0
  • Target Price
  • AVDL $18.86
  • FDUS N/A
  • AVG Volume (30 Days)
  • AVDL 1.5M
  • FDUS 177.3K
  • Earning Date
  • AVDL 03-03-2025
  • FDUS 03-06-2025
  • Dividend Yield
  • AVDL N/A
  • FDUS 10.46%
  • EPS Growth
  • AVDL N/A
  • FDUS N/A
  • EPS
  • AVDL N/A
  • FDUS 2.40
  • Revenue
  • AVDL $169,117,000.00
  • FDUS $146,154,000.00
  • Revenue This Year
  • AVDL $51.49
  • FDUS $13.81
  • Revenue Next Year
  • AVDL $32.18
  • FDUS $0.02
  • P/E Ratio
  • AVDL N/A
  • FDUS $9.20
  • Revenue Growth
  • AVDL 504.79
  • FDUS 12.33
  • 52 Week Low
  • AVDL $7.39
  • FDUS $18.41
  • 52 Week High
  • AVDL $19.09
  • FDUS $23.55
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 43.28
  • FDUS 41.80
  • Support Level
  • AVDL $7.45
  • FDUS $21.72
  • Resistance Level
  • AVDL $7.97
  • FDUS $23.48
  • Average True Range (ATR)
  • AVDL 0.37
  • FDUS 0.44
  • MACD
  • AVDL -0.01
  • FDUS -0.18
  • Stochastic Oscillator
  • AVDL 33.82
  • FDUS 20.22

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About FDUS Fidus Investment Corporation

Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investments is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.

Share on Social Networks: